Completed PHASE3 INTERVENTIONAL 3-arm NCT00129220

Trial of Olanzapine in Patients With Manic or Mixed Episode of Bipolar I Disorder

Placebo- and Haloperidol-Controlled Double-Blind Trial of Olanzapine in Patients With Manic or Mixed Episode of Bipolar I Disorder

Sponsor: Eli Lilly and Company

Conditions Bipolar Disorder

Interventions haloperidol olanzapine placebo

Updated 8 times since 2017 Last updated: Dec 10, 2010 Started: Jul 31, 2005 Primary completion: Jan 31, 2009 Completion: Jan 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Bipolar Disorder, this trial is completed. The trial is conducted by Eli Lilly and Company and has accumulated 8 data snapshots since 2005. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Dec 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Dec 2021 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jul 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company

Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aichi, Japan , Akita, Japan , Chiba, Japan , Fukuoka, Japan , Gunma, Japan , Hokkaido, Japan , Hyōgo, Japan , Kanagawa, Japan , Kumamoto, Japan , Nagano, Japan and 6 more locations